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Should ECG be required in young athletes?
Athletes’ hearts are adapted to chronic exercise 
training that may result in physiological increases in 
left-ventricular volume, left-ventricular hypertrophy, 
increased left-atrial volume, and right-ventricular 
structural changes, with preserved systolic and 
diastolic ventricular function and exercise ability.1,2 
The extent and variability of cardiac morphological 
changes in trained athletes varies with the type of 
exercise training, age, gender, environment, and body 
size. Genotype and diﬀ erent polymorphisms of the 
angiotensin-converting enzyme or angiotensinogen 
genes can result in diﬀ erent phenotypic expression in 
athletes’ hearts.
Results of resting 12-lead electrocardiogram (ECG) 
reﬂ ect the autonomic and structural changes resulting 
from training.3,4 Increased vagal tone usually results in 
sinus bradycardia, and can be associated with certain 
types of benign cardiac arrhythmias, ventricular 
hypertrophy, and repolarisation changes, such as ST 
segment elevation of the early repolarisation type and 
biphasic or inverted T waves, which occur in 2–4% of 
trained athletes aged 18–35 years.3 The commonness of 
ECG abnormalities in apparently healthy athletes with 
above average exercise performance contrasts sharply 
with the rareness of major cardiac pathology in these 
individuals and extremely rare incidents of sudden 
cardiac death.5
The requirement for an ECG (and in some countries, 
an echocardiogram and exercise test) to detect 
underlying cardiac pathology in young, apparently 
healthy athletes is controversial. In many European 
countries, not only is a careful history and physical 
examination needed, but also a 12-lead resting ECG 
is required before allowing competition, a position 
endorsed by the Lausanne recommendations for the 
International Olympic Committee (IOC).6,7 By contrast, 
the American Heart Association does not require 
or recommend routine 12-lead ECG as part of the 
precompetition assessment, unless the athlete fails a 
prescreening questionnaire and physical examination.8 
The position of the American Heart Association has 
recently been debated.9,10
The Summer Olympics will be held in Beijing, 
China, in August 2008. The decision to do an ECG 
as a precompetition requirement would have been 
considered by National Olympic Committees and 
International Federations well before the Beijing 
Olympics. However, how much prognostic accuracy 
a resting ECG adds to the detection of rare cardiac 
pathology and even more rare cardiac events that result 
in sudden cardiac death in apparently healthy athletes is 
unclear.
In a recent series, Antonio Pelliccia and colleagues11 
described the clinical course of 123 (1%) of 
12 550 trained athletes who had inverted T waves 
equal to or greater than 2 mm in at least three leads, 
predominantly V2–V6, without apparent cardiac 
disease; 81 subsequently had serial clinical, ECG, and 
echocardiographic studies.11 The athletes were followed 
up for a mean of 9 years (range 1–27 years) and were 
compared with 229 athletes matched for age and 
sex with normal ECG followed up for a similar time. 
Of the 81 athletes, 5 (6%) ultimately developed a 
cardiomyopathy, including one who died suddenly at 
age 24 years from arrhythmogenic right-ventricular 
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dysplasia, versus none in the control group. The 
prevalence of congenital defects in the 12 550 athletes 
was 0·03% and there were sudden cardiac arrests in two 
patients (0·01%), one of whom was resuscitated and 
the other of whom died.
Basavarajaiah and co-workers assessed the prevalence 
of hypertrophic cardiomyopathy in 3500 elite British 
athletes by use of clinical history, physical examination, 
screening ECG, and echocardiogram.12 1% had deep 
T-wave inversion and 1·5% had echocardiographic 
evidence of left-ventricular hypertrophy. Physiological 
adaptation to training explained the ﬁ ndings in 50; only 
three (0·08%) had left-ventricular hypertrophy with 
non-dilated left ventricles and associated T-wave 
inversion, each of whom had normal cardiac MRI, normal 
right-ventricular and left-ventricular structure and 
function, and normal 48-h ambulatory ECG monitoring. 
One athlete who agreed to stop training had normal 
ﬁ ndings after 12 weeks.
Routine non-invasive testing with an echocardiogram 
is a cost-ineﬃ  cient way to prospectively screen highly 
trained athletes, particularly those able to compete 
at Olympic level. The role of the resting ECG, a less 
expensive modality, as a prescreening requirement 
for diﬀ erent types of competitive sports in all younger 
athletes remains controversial,9,10 and the use of 
mandatory self-funded non-invasive test screening 
varies among diﬀ erent sports associations. Additional 
research into methods to cost-eﬀ ectively screen people 
involved in high-level exercise activities would be 
valuable.
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On April 22, it was brought to our attention that the 
published trial registration number provided by the 
authors of this study is incorrect.1 We have also been 
made aware of concerns about the ethical approval 
and conduct of this study, which are currently subject 
to investigations in Austria. Pending the outcome 
of these investigations, we issue an expression of 
concern about the article by Dr Hannes Strasser and 
colleagues.1
The Editors of The Lancet
1 Strasser H, Marksteiner R, Margreiter E, et al. Autologous myoblasts 
and ﬁ broblasts versus collagen for treatment of stress urinary 
incontinence in women: a randomised controlled trial. Lancet 2007; 
369: 2179–86.
Expression of concern—autologous myoblasts and 
ﬁ broblasts for treatment of stress urinary incontinence: 
a randomised controlled trial
